Epigenetic-dependent regulation of drug transport and metabolism: An update

Pharmacogenomics

Volumn 13, Issue 12, 2012, Pages 1373-1385

  Kacevska, Marina ^a   Ivanov, Maxim ^a   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

adverse drug reactions; cytochrome P450; drug transport; epigenetics; histone acetylation; microRNA; noncoding RNA; nuclear receptors

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABC TRANSPORTER; ARYLBUTYRIC ACID DERIVATIVE; CALCITRIOL; CARBAMAZEPINE; CISPLATIN; DAUNORUBICIN; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE PEROXIDASE 3; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; METHOTREXATE; PACLITAXEL; SALAZOSULFAPYRIDINE; TOPOTECAN; TRICHOSTATIN A; UNTRANSLATED RNA; VINBLASTINE; ZEBULARINE;

BREAST CANCER; CANCER SURVIVAL; COLON CANCER; CPG ISLAND; DNA METHYLATION; DRUG METABOLISM; DRUG RESISTANCE; DRUG RESPONSE; DRUG TRANSPORT; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; GPX3 GENE; GSTP1 GENE; HEAD AND NECK CANCER; HUMAN; LYMPHOMA; NONHUMAN; PROMOTER REGION; REVIEW; VDR GENE;

ANIMALS; BIOLOGICAL TRANSPORT; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84866308863     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.119     Document Type: Review

References (118)

1. Kouzarides T. Chromatin modifications and their function. Cell 128(4), 693-705 (2007 (Pubitemid 46273577)
2. Cedar H, Bergman Y. Linking DNA methylation and histone modification: Patterns and paradigms. Nat. Rev. Genet. 10(5), 295-304 (2009
3. Deaton AM, Bird A. CpG islands and the regulation of transcription. Genes Dev. 25(10), 1010-1022 (2011
4. Meissner A, Mikkelsen TS, Gu H et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 454(7205), 766-770 (2008
5. Wang Y, Leung FC. An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 20(7), 1170-1177 (2004 (Pubitemid 38660354)
6. Tahiliani M, Koh KP, Shen Y et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324(5929), 930-935 (2009
7. Kriaucionis S, Heintz N. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 324(5929), 929-930 (2009
8. Munzel M, Globisch D, Carell T. 5-hydroxymethylcytosine, the sixth base of the genome. Angew. Chem. Int. Ed. Engl. 50(29), 6460-6468 (2011
9. Li W, Liu M. Distribution of 5-hydroxymethylcytosine in different human tissues. J. Nucleic Acids 2011, 870726 (2011
10. Williams K, Christensen J, Pedersen MT et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473(7347), 343-348 (2011
11. Szulwach KE, Li X, Li Y et al. 5-hmC-mediated epigenetic dynamics during postnatal neurodevelopment and aging. Nat. Neurosci. 14(12), 1607-1616 (2011
12. Wossidlo M, Nakamura T, Lepikhov K et al. 5-hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat. Commun. 2, 241 (2011
13. He YF, Li BZ, Li Z et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333(6047), 1303-1307 (2011
14. ENCODE Project Consortium. The ENCODE (ENCyclopedia of DNA Elements) Project. Science 306(5696), 636-640 (2004
15. Esteller M. Non-coding RNAs in human disease. Nat. Rev. Genet. 12(12), 861-874 (2011
16. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat. Rev. Genet. 11(9), 597-610 (2010
17. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19(1), 92-105 (2009
18. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery: An intricate network. Biochim. Biophys. Acta 1799(10-12), 694-701 (2010
19. Nagano T, Fraser P. No-nonsense functions for long noncoding RNAs. Cell 145(2), 178-181 (2011
20. Chu C, Qu K, Zhong FL, Artandi SE, Chang HY. Genomic maps of long noncoding RNA occupancy reveal principles of RNA- chromatin interactions. Mol. Cell 44(4), 667-678 (2011
21. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 108(4), 475-487 (2002 (Pubitemid 34260873)
22. Khalil AM, Rinn JL. RNA-protein interactions in human health and disease. Semin. Cell Dev. Biol. 22(4), 359-365 (2011
23. Escamilla-Del-Arenal M, da Rocha ST, Heard E. Evolutionary diversity and developmental regulation of X-chromosome inactivation. Hum. Genet. 130(2), 307-327 (2011
24. Rinn JL, Kertesz M, Wang JK et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 129(7), 1311-1323 (2007 (Pubitemid 46962090)
25. Tsai MC, Manor O, Wan Y et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science 329(5992), 689-693 (2010
26. Kogo R, Shimamura T, Mimori K et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 71(20), 6320-6326 (2011
27. Yang Z, Zhou L, Wu LM et al. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann. Surg. Oncol. 18(5), 1243-1250 (2011
28. Kim K, Jutooru I, Chadalapaka G et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene doi:10.1038/onc.2012.193 (2012) (Epub ahead of print
29. Gupta RA, Shah N, Wang KC et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464(7291), 1071-1076 (2010
30. Morris KV. Non-coding RNAs, epigenetic memory and the passage of information to progeny. RNA Biol. 6(3), 242-247 (2009
31. Guttman M, Rinn JL. Modular regulatory principles of large non-coding RNAs. Nature 482(7385), 339-346 (2012
32. Koziol MJ, Rinn JL. RNA traffic control of chromatin complexes. Curr. Opin. Genet. Dev. 20(2), 142-148 (2010
33. Kacevska M, Ivanov M, Ingelman-Sundberg M. Perspectives on epigenetics and its relevance to adverse drug reactions. Clin. Pharmacol. Ther. 89(6), 902-907 (2011
34. Anttila S, Hakkola J, Tuominen P et al. Methylation of cytochrome P4501A1 promoter in the lung is associated with tobacco smoking. Cancer Res. 63(24), 8623-8628 (2003 (Pubitemid 38064036)
35. Tekpli X, Zienolddiny S, Skaug V, Stangeland L, Haugen A, Mollerup S. DNA methylation of the CYP1A1 enhancer is associated with smoking-induced genetic alterations in human lung. Int. J. Cancer 131(7), 1509-1516 (2011
36. Suter M, Abramovici A, Showalter L et al. In utero tobacco exposure epigenetically modifies placental CYP1A1 expression. Metabolism 59(10), 1481-1490 (2010
37. Kaut O, Schmitt I, Wullner U. Genome-scale methylation analysis of Parkinson's disease patients' brains reveals DNA hypomethylation and increased mRNA expression of cytochrome P450 2E1. Neurogenetics 13(1), 87-91 (2012
38. Shahabi HN, Andersson DR, Nissbrandt H. Cytochrome P450 2E1 in the substantia nigra: Relevance for dopaminergic neurotransmission and free radical production. Synapse 62(5), 379-388 (2008 (Pubitemid 351451806)
39. Riedl AG, Watts PM, Jenner P, Marsden CD. P450 enzymes and Parkinson's disease: The story so far. Mov. Disord. 13(2), 212-220 (1998 (Pubitemid 28127794)
40. Wu Y, Shi X, Liu Y et al. Histone deacetylase 1 is required for carbamazepine-induced CYP3A4 expression. J. Pharm. Biomed. Anal. 58, 78-82 (2012
41. Ramamoorthy A, Skaar TC. In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes. Drug Metab. Lett. 5(2), 126-131 (2011
42. Yokoi T, Nakajima M. Toxicological implications of modulation of gene expression by microRNAs. Toxicol. Sci. 123(1), 1-14 (2011
43. Nakajima M, Yokoi T. MicroRNAs from biology to future pharmacotherapy: Regulation of cytochrome P450s and nuclear receptors. Pharmacol. Ther. 131(3), 330-337 (2011
44. Rukov JL, Shomron N. MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response. Trends Mol. Med. 17(8), 412-423 (2011
45. Zhang W, Dolan ME. The emerging role of microRNAs in drug responses. Curr. Opin. Mol. Ther. 12(6), 695-702 (2010
46. Giovannetti E, Erozenci A, Smit J, Danesi R, Peters GJ. Molecular mechanisms underlying the role of microRNAs (miRNAs) in anticancer drug resistance and implications for clinical practice. Crit. Rev. Oncol. Hematol. 81(2), 103-122 (2012
47. Nagano T, Mitchell JA, Sanz LA et al. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 322(5908), 1717-1720 (2008
48. Zwart R, Sleutels F, Wutz A, Schinkel AH, Barlow DP. Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes. Genes Dev. 15(18), 2361-2366 (2001 (Pubitemid 32899740)
49. Sleutels F, Zwart R, Barlow DP. The non-coding Air RNA is required for silencing autosomal imprinted genes. Nature 415(6873), 810-813 (2002 (Pubitemid 34150505)
50. Yamasaki Y, Kayashima T, Soejima H et al. Neuron-specific relaxation of Igf2r imprinting is associated with neuron-specific histone modifications and lack of its antisense transcript Air. Hum. Mol. Genet. 14(17), 2511-2520 (2005 (Pubitemid 41236064)
51. Gagnon JF, Bernard O, Villeneuve L, Tetu B, Guillemette C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin. Cancer Res. 12(6), 1850-1858 (2006
52. Ferreri AJ, Dell'Oro S, Capello D et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br. J. Haematol. 126(5), 657-664 (2004 (Pubitemid 39221300)
53. Livide G, Epistolato MC, Amenduni M et al. Epigenetic and copy number variation analysis in retinoblastoma by MS-MLPA. Pathol. Oncol. Res. 18(3), 703-712 (2012
54. Aydemir F, Yurtcu E, Balci TB, Sahin FI, Gulsen S, Altinors N. Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients. Genet. Test Mol. Biomarkers 16(5), 335-340 (2012
55. Gumy-Pause F, Pardo B, Khoshbeen-Boudal M et al. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma. Genes Chromosomes Cancer 51(2), 174-185 (2012
56. Enokida H, Shiina H, Urakami S et al. Multigene methylation analysis for detection and staging of prostate cancer. Clin. Cancer Res. 11(18), 6582-6588 (2005 (Pubitemid 41338998)
57. Yuan Y, Qian ZR, Sano T et al. Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas. Mod. Pathol. 21(7), 856-865 (2008 (Pubitemid 351896660)
58. Moribe T, Iizuka N, Miura T et al. Methylation of multiple genes as molecular markers for diagnosis of a small, well-differentiated hepatocellular carcinoma. Int. J. Cancer 125(2), 388-397 (2009
59. Hashad DI, Hashad MM, Talaat IM, Ibrahim MA. Role of glutathione-S- transferase P1 hypermethylation in molecular detection of prostate cancer. Genet. Test Mol. Biomarkers 15(10), 667-670 (2011
60. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2́-deoxycytidine efficacy in human prostate cancer cells. PLoS ONE 6(9), e25634 (2011
61. Ronneberg JA, Tost J, Solvang HK et al. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Res. 68(14), 5562-5571 (2008
62. Dejeux E, Ronneberg JA, Solvang H et al. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Mol. Cancer 9, 68 (2010
63. Kalinina EV, Chernov NN, Saprin AN, Kotova YN, Remizov VI, Shcherbak NP. Expression of genes for redox-dependent glutathione S-transferase isoforms GSTP1-1 and GSTA4-4 in tumor cell during the development doxorubicin resistance. Bull. Exp. Biol. Med. 143(3), 328-330 (2007 (Pubitemid 47323249)
64. Brigelius-Flohe R, Kipp A. Glutathione peroxidases in different stages of carcinogenesis. Biochim. Biophys. Acta 1790(11), 1555-1568 (2009
65. Wang H, Luo K, Tan LZ et al. p53-induced-gene 3 mediates cell death induced by glutathione peroxidase 3. J. Biol. Chem. 287(20), 16890-16902 (2012
66. Peng DF, Razvi M, Chen H et al. DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. Gut 58(1), 5-15 (2009
67. Lee OJ, Schneider-Stock R, McChesney PA et al. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 7(9), 854-861 (2005
68. Yu YP, Yu G, Tseng G et al. Glutathione peroxidase 3, deleted or methylated in prostate cancer, suppresses prostate cancer growth and metastasis. Cancer Res. 67(17), 8043-8050 (2007 (Pubitemid 47395138)
69. Chen B, Rao X, House MG, Nephew KP, Cullen KJ, Guo Z. GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Lett. 309(1), 37-45 (2011
70. Saga Y, Ohwada M, Suzuki M et al. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol. Rep. 20(6), 1299-1303 (2008
71. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol. Res. 11(6), 255-264 (1999
72. Whitcomb BP, Mutch DG, Herzog TJ, Rader JS, Gibb RK, Goodfellow PJ. Frequent HOXA11 and THBS2 promoter methylation, and a methylator phenotype in endometrial adenocarcinoma. Clin. Cancer Res. 9(6), 2277-2287 (2003 (Pubitemid 36687653)
73. Marik R, Fackler M, Gabrielson E et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol. Ther. 10(1), 44-53 (2010
74. Banwell CM, Singh R, Stewart PM, Uskokovic MR, Campbell MJ. Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Recent Results Cancer Res. 164, 83-98 (2003
75. Liu FS. Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J. Obstet. Gynecol. 48(3), 239-244 (2009
76. Baker EK, El-Osta A. MDR1, chemotherapy and chromatin remodeling. Cancer Biol. Ther. 3(9), 819-824 (2004 (Pubitemid 41351044)
77. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene 24(54), 8061-8075 (2005 (Pubitemid 41746749)
78. Bram EE, Stark M, Raz S, Assaraf YG. Chemotherapeutic drug-induced ABCG2 promoter demethylation as a novel mechanism of acquired multidrug resistance. Neoplasia 11(12), 1359-1370 (2009
79. Hauswald S, Duque-Afonso J, Wagner MM et al. Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes. Clin. Cancer Res. 15(11), 3705-3715 (2009
80. Wang XM, Greiner TC, Bibikova M et al. Identification and functional relevance of de novo DNA methylation in cancerous B-cell populations. J. Cell. Biochem. 109(4), 818-827 (2010
81. Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp. Biol. Med. (Maywood) 235(1), 32-39 (2010
82. Conway K, Edmiston SN, Khondker ZS et al. DNA-methylation profiling distinguishes malignant melanomas from benign nevi. Pigment Cell Melanoma Res. 24(2), 352-360 (2011
83. Huang ZH, Hu Y, Hua D, Wu YY, Song MX, Cheng ZH. Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinoma. Exp. Mol. Pathol. 91(3), 702-707 (2011
84. Baker EK, El-Osta A. Epigenetic regulation of multidrug resistance 1 gene expression: Profiling CpG methylation status using bisulphite sequencing. Methods Mol. Biol. 596, 183-198 (2010
85. Sharma G, Mirza S, Parshad R et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin. Biochem. 43(4-5), 373-379 (2010
86. Muggerud AA, Ronneberg JA, Warnberg F et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 12(1), R3 (2010
87. Huo H, Magro PG, Pietsch EC, Patel BB, Scotto KW. Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance. Cancer Res. 70(21), 8726-8735 (2010
88. Schaeffeler E, Hellerbrand C, Nies AT et al. DNA methylation is associated with downregulation of the organic cation transporter OCT1 (SLC22A1) in human hepatocellular carcinoma. Genome. Med. 3(12), 82 (2011
89. Saito J, Hirota T, Kikunaga N, Otsubo K, Ieiri I. Interindividual differences in placental expression of the SLC22A2 (OCT2) gene: Relationship to epigenetic variations in the 5́-upstream regulatory region. J. Pharm. Sci. 100(9), 3875-3883 (2011
90. Chen L, Hong C, Chen EC et al. Genetic and epigenetic regulation of the organic cation transporter 3, SLC22A3. Pharmacogenom. J. doi:10.1038/tpj.2011.60 (2012) (Epub ahead of print
91. Jin L, Kikuchi R, Saji T, Kusuhara H, Sugiyama Y. Regulation of tissue-specific expression of renal organic anion transporters by hepatocyte nuclear factor 1 a/b and DNA methylation. J. Pharmacol. Exp. Ther. 340(3), 648-655 (2012
92. Lee A, Nofziger C, Dossena S, Vanoni S, Diasio R, Paulmichl M. Methylation of the human pendrin promoter. Cell Physiol. Biochem. 28(3), 397-406 (2011
93. Candelaria M, de la Cruz-Hernandez E, Perez-Cardenas E, Trejo-Becerril C, Gutierrez-Hernandez O, Duenas-Gonzalez A. Pharmacogenetics and pharmacoepigenetics of gemcitabine. Med. Oncol. 27(4), 1133-1143 (2010
94. Silviera ML, Smith BP, Powell J, Sapienza C. Epigenetic differences in normal colon mucosa of cancer patients suggest altered dietary metabolic pathways. Cancer Prev. Res. (Phila.) 5(3), 374-384 (2012
95. Belanger AS, Tojcic J, Harvey M, Guillemette C. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Mol. Biol. 11, 9 (2010
96. Eissa S, Swellam M, El-Khouly IM et al. Aberrant methylation of RARb2 and APC genes in voided urine as molecular markers for early detection of bilharzial and nonbilharzial bladder cancer. Cancer Epidemiol. Biomarkers Prev. 20(8), 1657-1664 (2011
97. Habano W, Gamo T, Terashima J et al. Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer 11, 81 (2011
98. Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 66(18), 9090-9098 (2006 (Pubitemid 44521128)
99. Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. Human CYP2E1 is regulated by miR-378. Biochem. Pharmacol. 79(7), 1045-1052 (2010
100. Takagi S, Nakajima M, Mohri T, Yokoi T. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J. Biol. Chem. 283(15), 9674-9680 (2008
101. Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab. Dispos. Biol. Fate Chem. 37(10), 2112-2117 (2009
102. Yu X, Dhakal IB, Beggs M et al. Functional genetic variants in the 3́-untranslated region of sulfotransferase isoform 1A1 (SULT1A1) and their effect on enzymatic activity. Toxicol. Sci. Official J. Soc. Toxicol. 118(2), 391-403 (2010
103. Wijesekara N, Zhang LH, Kang MH et al. miR-33a modulates ABCA1 expression, cholesterol accumulation, and insulin secretion in pancreatic islets. Diabetes 61(3), 653-658 (2012
104. Najafi-Shoushtari SH, Kristo F, Li Y et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 328(5985), 1566-1569 (2010
105. Kim J, Yoon H, Ramirez CM, Lee SM, Hoe HS, Fernandez-Hernando C. miR-106b impairs cholesterol efflux and increases Ab levels by repressing ABCA1 expression. Exp. Neurol. 235(2), 476-483 (2012
106. Ramirez CM, Davalos A, Goedeke L et al. MicroRNA-758 regulates cholesterol efflux through posttranscriptional repression of ATP-binding cassette transporter A1. Arterioscler. Thromb. Vasc. Biol. 31(11), 2707-2714 (2011
107. Borel F, Han R, Visser A et al. Adenosine triphosphate-binding cassette transporter genes up-regulation in untreated hepatocellular carcinoma is mediated by cellular microRNAs. Hepatology 55(3), 821-832 (2012
108. Bartoszewski R, Brewer JW, Rab A et al. The unfolded protein response (UPR)- activated transcription factor X-box-binding protein 1 (XBP1) induces microRNA-346 expression that targets the human antigen peptide transporter 1 (TAP1) mRNA and governs immune regulatory genes. J. Biol. Chem. 286(48), 41862-41870 (2011
109. Bitarte N, Bandres E, Boni V et al. microRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 29(11), 1661-1671 (2011
110. Li Z, Hu S, Wang J et al. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol. Oncol. 119(1), 125-130 (2010
111. Liao R, Sun J, Zhang L et al. MicroRNAs play a role in the development of human hematopoietic stem cells. J. Cell. Biochem. 104(3), 805-817 (2008 (Pubitemid 351830831)
112. Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM. Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells. Biochem. Pharmacol. 81(6), 783-792 (2011
113. Pan YZ, Morris ME, Yu AM. MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol. Pharmacol. 75(6), 1374-1379 (2009
114. Liang Z, Wu H, Xia J et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem. Pharmacol. 79(6), 817-824 (2010
115. Haenisch S, Laechelt S, Bruckmueller H et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol. Pharmacol. 80(2), 314-320 (2011
116. Gillen AE, Gosalia N, Leir SH, Harris A. MicroRNA regulation of expression of the cystic fibrosis transmembrane conductance regulator gene. Biochem. J. 438(1), 25-32 (2011
117. Dalmasso G, Nguyen HT, Yan Y et al. MicroRNA-92b regulates expression of the oligopeptide transporter PepT1 in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 300(1), G52-G59 (2011
118. Li KK, Pang JC, Ching AK et al. miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1. Hum. Pathol. 40(9), 1234-1243 (2009